MCID: NNT008
MIFTS: 39

Neonatal Abstinence Syndrome

Categories: Mental diseases, Respiratory diseases

Aliases & Classifications for Neonatal Abstinence Syndrome

Summaries for Neonatal Abstinence Syndrome

Disease Ontology : 12 A withdrawal disorder that is characterized by a group of problems that occur in a newborn who was exposed to addictive illegal or prescription drugs while in the mother's womb or postnatally following the discontinuance of drug treatment.

MalaCards based summary : Neonatal Abstinence Syndrome, also known as drug withdrawal syndrome in newborn, is related to pain agnosia and disease of mental health. An important gene associated with Neonatal Abstinence Syndrome is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Paroxetine Pathway, Pharmacokinetics. The drugs Clonidine and Naloxone have been mentioned in the context of this disorder. Affiliated tissues include brain and skin.

Related Diseases for Neonatal Abstinence Syndrome

Graphical network of the top 20 diseases related to Neonatal Abstinence Syndrome:



Diseases related to Neonatal Abstinence Syndrome

Symptoms & Phenotypes for Neonatal Abstinence Syndrome

Drugs & Therapeutics for Neonatal Abstinence Syndrome

Drugs for Neonatal Abstinence Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4205-90-7 2803
2
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 465-65-6 5284596
3
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 644073 40400
4
Opium Approved, Illicit Phase 4 8008-60-4
5
Methadone Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 76-99-3 4095
6
Phenobarbital Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 50-06-6 4763
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 93-14-1 3516
8
Loperamide Approved Phase 4 53179-11-6 3955
9
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
10
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
11
tannic acid Approved Phase 4,Phase 3,Phase 2 1401-55-4
12
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
13
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 1,Phase 2
22 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
23 Antidiarrheals Phase 4
24 Opium Poppy Phase 4
25 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 GABA Modulators Phase 4,Phase 3,Phase 2,Not Applicable
27 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Not Applicable
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Not Applicable
30 Anticonvulsants Phase 4,Phase 3,Phase 2,Not Applicable
31 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
33 Antitussive Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Hypnotics and Sedatives Phase 4,Phase 3,Phase 2,Not Applicable
35 GABA Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Not Applicable
37 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Not Applicable
38 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Not Applicable
39 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Sympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
43 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Not Applicable
44
Heroin Phase 4,Phase 2 5462328
45
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
46
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
47
Chamomile Approved, Experimental, Investigational Phase 3
48
Chlorpromazine Approved, Investigational, Vet_approved Phase 3 50-53-3 2726
49
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
50
Cocaine Approved, Illicit Phase 2, Phase 3 50-36-2 446220 5760

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Treatment of Neonatal Abstinence Syndrome Completed NCT01723722 Phase 4 Methadone;Diluted Deodorized Tincture of Opium
2 NAS Treatment - Opiate Versus Non-Opiate Completed NCT01734551 Phase 4 Morphine;Clonidine
3 Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal Completed NCT01804075 Phase 4 Methadone;Morphine
4 Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy Recruiting NCT03092011 Phase 4 Clonidine;Morphine Sulfate
5 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Recruiting NCT02851303 Phase 4 Morphine;Methadone
6 Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology Recruiting NCT03740243 Phase 4 Buprenorphine/naloxone;Buprenorphine
7 Clonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome Suspended NCT03762317 Phase 4 Clonidine;Placebo
8 Improving Outcomes in Neonatal Abstinence Syndrome Completed NCT01958476 Phase 3 Neonatal Morphine Solution;Methadone;Phenobarbital
9 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels Completed NCT03097484 Phase 3 lavender and chamomile essential oils
10 Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome Completed NCT01452789 Phase 3 sublingual buprenorphine;oral morphine
11 Fetal and Infant Effects of Maternal Buprenorphine Treatment Completed NCT01561079 Phase 2, Phase 3 Buprenorphine
12 Maternal Acupuncture for Substance Abuse Completed NCT00225316 Phase 3
13 How to Treat Opiate Withdrawal in Neonates Completed NCT02810782 Phase 3 Phenobarbital;Chlorpromazine;Morphine
14 Tobacco Use in Opioid Agonist Treated Pregnant Women Completed NCT00497068 Phase 2, Phase 3
15 RCT Comparing Methadone and Buprenorphine in Pregnant Women Completed NCT00271219 Phase 3 Methadone;Buprenorphine
16 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
17 Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain Recruiting NCT03396588 Phase 3 Clonidine;Morphine
18 Medication Treatment for Opioid Use Disorder in Expectant Mothers Not yet recruiting NCT03918850 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
19 Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study Not yet recruiting NCT03911739 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
20 Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study Not yet recruiting NCT03911466 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
21 Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants Terminated NCT01360450 Phase 2, Phase 3 Clonidine HCL;saline
22 Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study Unknown status NCT02249026 Phase 1, Phase 2 BZDs + opiate exposure treated with BPN;Opiates exposure treated with BPN
23 Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome Completed NCT00510016 Phase 2 Clonidine HCL
24 Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS) Completed NCT01708707 Phase 2 Buprenorphine;Morphine Sulfate
25 RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants Completed NCT02178189 Phase 2
26 How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women Completed NCT01801475 Phase 1, Phase 2 Ondansetron
27 Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women Recruiting NCT01965704 Phase 2 Ondansetron;Placebo
28 Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome Recruiting NCT03670160 Phase 2 Phenobarbital;Clonidine
29 Methadone Demonstration Project Recruiting NCT03134703 Phase 2 Methadone;Morphine
30 Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure Recruiting NCT03608696 Phase 1, Phase 2 Buprenorphine
31 Maternal Buprenorphine-naloxone Treatment and the Infant Recruiting NCT03291847 Phase 2 Buprenorphine Naloxone;Methadone
32 Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines Completed NCT01671410 Phase 1 oral morphine;sublingual buprenorphine
33 Buprenorphine for the Treatment of Neonatal Abstinence Syndrome Completed NCT00521248 Phase 1 buprenorphine;Oral morphine solution
34 Donor Human Milk in Neonatal Abstinence Syndrome Completed NCT02182973
35 Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome Completed NCT02872077 Not Applicable
36 The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome Completed NCT01754324 Methadone
37 Vagal Tone and Neonatal Abstinence Syndrome Completed NCT00496951
38 Role of Low Lactose Infant Formula In The Management of Neonatal Abstinence Syndrome Completed NCT03549936 Not Applicable
39 Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies Completed NCT02062151 Not Applicable
40 Weighted Blankets With Infants With NAS Completed NCT03113656 Not Applicable
41 Interest of Concentrations in Meconium of Buprenorphine and Methadone as a Prognostic Factor of NAS Outcome Completed NCT03334981
42 Buprenorphine Dose Adjustments and Gestational Age Completed NCT03028883
43 Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers Completed NCT01889121
44 The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1 Completed NCT00218621
45 RESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure Completed NCT02334111 Not Applicable
46 Fetal Neurobehavior in Poly-drug Dependent Women Completed NCT00653692
47 Fetal Neurobehavioral Development in Methadone Maintained Pregnancies Completed NCT00067184
48 The Effect of Fetal Gender on Maternal Substance Abuse Treatment Completed NCT00882648
49 Conflict Between Maternal Autonomy and Child Health in Substance-use Completed NCT02797990
50 Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome Recruiting NCT03533985 Not Applicable

Search NIH Clinical Center for Neonatal Abstinence Syndrome

Cochrane evidence based reviews: neonatal abstinence syndrome

Genetic Tests for Neonatal Abstinence Syndrome

Anatomical Context for Neonatal Abstinence Syndrome

MalaCards organs/tissues related to Neonatal Abstinence Syndrome:

42
Brain, Skin

Publications for Neonatal Abstinence Syndrome

Articles related to Neonatal Abstinence Syndrome:

(show top 50) (show all 412)
# Title Authors Year
1
Evaluation of State-Mandated Reporting of Neonatal Abstinence Syndrome - Six States, 2013-2017. ( 30629576 )
2019
2
Addressing rural health disparities in neonatal abstinence syndrome: population-based surveillance and public policy. ( 30636770 )
2019
3
Pharmacological Treatments for Neonatal Abstinence Syndrome: A Systematic Review and Network Meta-analysis. ( 30667476 )
2019
4
Pharmacologic Treatment for Neonatal Abstinence Syndrome: Which Medication Is Best? ( 30667482 )
2019
5
Association Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural Location, and Neonatal Abstinence Syndrome. ( 30694320 )
2019
6
The genetics and epigenetics of Neonatal Abstinence Syndrome. ( 30709700 )
2019
7
Amplitude-integrated EEG use in neonatal abstinence syndrome: a pilot study. ( 30720377 )
2019
8
Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). ( 30745219 )
2019
9
Neonatal abstinence syndrome. ( 30773241 )
2019
10
Opioid Use in Pregnant Women and Neonatal Abstinence Syndrome-A Review of the Literature. ( 30781484 )
2019
11
Leveraging Existing Birth Defects Surveillance Infrastructure to Build Neonatal Abstinence Syndrome Surveillance Systems - Illinois, New Mexico, and Vermont, 2015-2016. ( 30789880 )
2019
12
An unusual cause for neonatal abstinence syndrome. ( 30792593 )
2019
13
The effect of maternal antidepressants on third trimester uteroplacental hemodynamics and the neonatal abstinence syndrome: a retrospective cohort study. ( 30798375 )
2019
14
The Possibility of Early Discharge for Newborns Being Monitored for Neonatal Abstinence Syndrome Based on Modified Finnegan Score Distributions. ( 30813757 )
2019
15
Neonatal Abstinence Syndrome. ( 30819342 )
2019
16
Shining a Light: Integrating Protocols Into Clinical Practice for Treatment of Neonatal Abstinence Syndrome. ( 30830002 )
2019
17
Eat, Sleep, Console Approach: A Family-Centered Model for the Treatment of Neonatal Abstinence Syndrome. ( 30855311 )
2019
18
Associations between Orofacial Clefting and Neonatal Abstinence Syndrome. ( 30859050 )
2019
19
Validation of hospital discharge coding for neonatal abstinence syndrome. ( 30924956 )
2019
20
Models of care for neonatal abstinence syndrome: What works? ( 30926259 )
2019
21
Systematic mixed-study review of nonpharmacological management of neonatal abstinence syndrome. ( 30938466 )
2019
22
EEG Findings in Infants With Neonatal Abstinence Syndrome Presenting With Clinical Seizures. ( 30984728 )
2019
23
Occupational Therapy Management Strategies for Infants With Neonatal Abstinence Syndrome: Scoping Review. ( 30987496 )
2019
24
Maternal breast milk feeding and length of treatment in infants with neonatal abstinence syndrome. ( 30988400 )
2019
25
Identification of neonatal abstinence syndrome in the community: Infants born into Canada's opioid crisis. ( 30996597 )
2019
26
Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. ( 31010564 )
2019
27
A Scoping Review of Acupuncture as a Potential Intervention for Neonatal Abstinence Syndrome. ( 31031873 )
2019
28
Systematic Review of Newborn Feeding Method and Outcomes Related to Neonatal Abstinence Syndrome. ( 31034790 )
2019
29
Neonatal Abstinence Syndrome: a systematic review of current databases and registries. ( 31092074 )
2019
30
Therapeutic approaches for neonatal abstinence syndrome: a systematic review of randomized clinical trials. ( 31093953 )
2019
31
Early Intervention Referral and Enrollment Among Infants with Neonatal Abstinence Syndrome. ( 31107767 )
2019
32
Comparison of outcomes between morphine and concomitant morphine and clonidine treatments for neonatal abstinence syndrome. ( 29972601 )
2019
33
Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to 'kratom'. ( 30149482 )
2019
34
A Longitudinal Healthcare Use Profile of Children with a History of Neonatal Abstinence Syndrome. ( 30270164 )
2019
35
Capturing the statewide incidence of neonatal abstinence syndrome in real time: the West Virginia experience. ( 30287893 )
2019
36
Prenatal Opioid Exposure, Neonatal Abstinence Syndrome/Neonatal Opioid Withdrawal Syndrome, and Later Child Development Research: Shortcomings and Solutions. ( 30334926 )
2019
37
Maternal Opioid Use Disorder and Neonatal Abstinence Syndrome Among Rural US Residents, 2007-2014. ( 30370563 )
2019
38
Could prenatal food insecurity influence neonatal abstinence syndrome severity? ( 30422365 )
2019
39
Mental Disorders Among Children Born With Neonatal Abstinence Syndrome. ( 30453858 )
2019
40
Positive Predictive Value of Administrative Data for Neonatal Abstinence Syndrome. ( 30514781 )
2019
41
Neonatal Head Circumference in Newborns With Neonatal Abstinence Syndrome. ( 30530638 )
2019
42
Morphine treatment for neonatal abstinence syndrome: huge dosing variability underscores the need for a better clinical study design. ( 28260350 )
2019
43
Clinical Opinion Letters Regarding Breastfeeding and Neonatal Abstinence Syndrome for Child Apprehension Family Court Proceedings. ( 30543758 )
2018
44
Morphine and Methadone for Neonatal Abstinence Syndrome: A Systematic Review. ( 30567886 )
2018
45
Factors associated with the prevalence of neonatal abstinence syndrome in West Virginia. ( 30629281 )
2018
46
Evaluation of the Cardiovascular Effects of Clonidine in Neonates Treated for Neonatal Abstinence Syndrome. ( 30697133 )
2018
47
Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. ( 28685864 )
2018
48
A Quality Improvement Initiative to Increase Scoring Consistency and Accuracy of the Finnegan Tool: Challenges in Obtaining Reliable Assessments of Drug Withdrawal in Neonatal Abstinence Syndrome. ( 29045256 )
2018
49
Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome. ( 29048415 )
2018
50
Buprenorphine in Neonatal Abstinence Syndrome. ( 29105752 )
2018

Variations for Neonatal Abstinence Syndrome

Expression for Neonatal Abstinence Syndrome

Search GEO for disease gene expression data for Neonatal Abstinence Syndrome.

Pathways for Neonatal Abstinence Syndrome

GO Terms for Neonatal Abstinence Syndrome

Cellular components related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.58 COMT OPRK1 OPRM1
2 perikaryon GO:0043204 9.43 OPRK1 OPRM1
3 axon terminus GO:0043679 9.37 OPRD1 OPRK1
4 integral component of postsynaptic membrane GO:0099055 9.32 OPRK1 OPRM1
5 integral component of synaptic vesicle membrane GO:0030285 9.26 OPRD1 OPRK1
6 dendrite membrane GO:0032590 9.16 OPRD1 OPRM1
7 integral component of presynaptic membrane GO:0099056 9.13 OPRD1 OPRK1 OPRM1
8 spine apparatus GO:0097444 8.62 OPRD1 OPRM1

Biological processes related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.58 OPRD1 OPRK1 OPRM1
2 response to ethanol GO:0045471 9.57 OPRK1 OPRM1
3 locomotory behavior GO:0007626 9.56 OPRK1 OPRM1
4 response to estrogen GO:0043627 9.55 COMT OPRK1
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.54 OPRD1 OPRM1
6 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.54 OPRD1 OPRK1 OPRM1
7 sensory perception of pain GO:0019233 9.52 OPRK1 OPRM1
8 response to cocaine GO:0042220 9.51 OPRK1 OPRM1
9 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.5 OPRD1 OPRK1 OPRM1
10 response to radiation GO:0009314 9.49 OPRK1 OPRM1
11 response to morphine GO:0043278 9.48 OPRK1 OPRM1
12 estrous cycle GO:0044849 9.46 OPRK1 OPRM1
13 sensory perception GO:0007600 9.43 OPRK1 OPRM1
14 eating behavior GO:0042755 9.33 OPRD1 OPRK1 OPRM1
15 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.26 OPRK1 OPRM1
16 opioid receptor signaling pathway GO:0038003 9.13 OPRD1 OPRK1 OPRM1
17 regulation of sensory perception of pain GO:0051930 8.92 COMT OPRD1 OPRK1 OPRM1

Molecular functions related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor serine/threonine kinase binding GO:0033612 9.16 OPRD1 OPRK1
2 neuropeptide binding GO:0042923 9.13 OPRD1 OPRK1 OPRM1
3 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Neonatal Abstinence Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....